FunPep Company Limited

Tokyo Stock Exchange 4881.T

FunPep Company Limited EPS (Diluted) for the year ending December 31, 2023: USD -0.28

FunPep Company Limited EPS (Diluted) is USD -0.28 for the year ending December 31, 2023, a 39.65% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.
  • FunPep Company Limited EPS (Diluted) for the year ending December 31, 2022 was USD -0.47, a -35.36% change year over year.
  • FunPep Company Limited EPS (Diluted) for the year ending December 31, 2021 was USD -0.34, a 12.00% change year over year.
  • FunPep Company Limited EPS (Diluted) for the year ending December 31, 2020 was USD -0.39, a -109.69% change year over year.
  • FunPep Company Limited EPS (Diluted) for the year ending December 31, 2019 was USD -0.19.
Key data
Date EPS (Diluted) Shares (Diluted, Weighted) Shares (Basic, Weighted) Revenue
Market news
Loading...
Tokyo Stock Exchange: 4881.T

FunPep Company Limited

CEO Mr. Toshimi Miyoshi Ph.D., Pharm.D.
IPO Date Dec. 25, 2020
Location Japan
Headquarters No.7 Mizuho Building
Employees 15
Sector Health Care
Industries
Description

FunPep Company Limited engages in the research and development of pharmaceuticals drugs, functional cosmetics, and medical devices based on functional peptides. The company is developing SR-0379, a functional peptide for skin ulcer; FPP003, an antibody-inducing peptide that is in Phase II clinical study for the treatment of psoriasis in Australia, as well as phase II clinical trial for ankylosing spondylitis in Japan; and FPP004X, an antibody-inducing peptide for pollinosis. It is also developing FPP006, a corona peptide vaccine; and FPP005, a antibody including peptide for psoriasis. FunPep Company Limited was incorporated in 2013 and is based in Tokyo, Japan.

StockViz Staff

January 15, 2025

Any question? Send us an email